FDA-Approved MedicationUpdated September 2026

Ozempic Guide

Name: Ozempic: Cost, Dosing & Side Effects
Creator: Ruth Calder
Published: 2026-06-04

Ozempic is the brand-name formulation of semaglutide FDA-approved for type 2 diabetes management, though it has become widely prescribed off-label for weight loss. It is available in doses of 0.5mg, 1mg, and 2mg weekly, and is manufactured by Novo Nordisk. Ozempic also carries an FDA indication to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor

Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed September 2026

At a Glance

Generic Name	Semaglutide
Brand Names	Ozempic
FDA Status	FDA-approved for glycemic control in type 2 diabetes (December 2017); FDA-approved to reduce cardiovascular risk in adults with T2DM and established CVD (2020). Weight loss is off-label use.^[1]
Approval Date	December 5, 2017^[1]

How Ozempic Works

Ozempic activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, and reduce blood sugar levels. The same mechanism that controls blood glucose also suppresses appetite and slows gastric emptying, producing significant weight loss as a secondary effect. At 1–2mg doses, Ozempic delivers strong appetite suppression comparable to Wegovy's lower dose range.^[2]^[3]

Dosing Schedule

Ozempic uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label^[1].

Weeks 1–40.25mg/week

Weeks 5+0.5mg/week

After 4+ weeks at 0.5mg1mg/week (if needed)

After 4+ weeks at 1mg2mg/week (max)

Side Effects

Common: nausea, vomiting, diarrhea, stomach pain, constipation. Injection site reactions are common in early weeks. Serious (rare): pancreatitis, diabetic retinopathy worsening, kidney injury, hypoglycemia when combined with sulfonylureas or insulin. Thyroid C-cell tumor risk noted in animal studies.^[1]^[2]

Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information^[1].

Clinical Trial Results

In the SUSTAIN-6 cardiovascular trial, Ozempic reduced the risk of major cardiovascular events by 26% vs. placebo (Marso et al. NEJM 2016, PMID 27633186). For weight loss specifically, the STEP-8 head-to-head trial (Rubino et al. JAMA 2022, PMID 34962517) used semaglutide 2.4 mg — the Wegovy dose, not the Ozempic 1 mg dose — and showed 15.8% weight loss vs 6.4% for liraglutide 3 mg. The approvals do not overlap: type 2 diabetes is the whole of Ozempic's label, and chronic weight management belongs to Wegovy, the other semaglutide.^[2]
Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

CompoundedSemaglutideTirzepatideNAD+

Get Started Read full DudeMeds review →

8.6/ 10

Care Bare Rx

Best for: knowing which pharmacy fills the vial: it names Belmar Pharmacy

★★★★☆4.3/5

Editorial score · methodology

$199/mo

CompoundedSemaglutideTirzepatideNAD+

Get Started Read full Care Bare Rx review →

Cost Comparison

Ozempic cost & pricing →Savings & coupons →Dosing & titration →How to get it →Storage & handling →Alternatives →Manufacturer coupon →

What each seller in the register charges to start on a compounded GLP-1, cheapest at the top. Compounded semaglutide from licensed 503A and 503B pharmacies is legal under federal compounding law^[4], and the rules have historically loosened further for any molecule sitting on the FDA Drug Shortage List^[5]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502^[6]. What you actually pay moves with your dose and with whatever promotion happens to be running.

Provider	Form	Starting Price	Link
GOAL.MD	brand	$244/mo	Visit
Cost Plus Drugs	brand	$279/mo	Visit
Navio MD	brand	$345/mo	Visit
Care Bare Rx	brand	$705/mo	Visit
Vital Edge	brand	$705/mo	Visit
Push Health	brand	$950/mo	Visit
Vaylen	brand	$997/mo	Visit
altRX	brand	$1,149/mo	Visit
Levity	brand	$1,199/mo	Visit
Healthicare	brand	$1,200/mo	Visit

Show all 24 Ozempic sellers

Ozempic sellers 11 to 24, cheapest first
Aquivia Health	brand	$1,299/mo	Visit
Gala	brand	$1,299/mo	Visit
Luvo Health	brand	$1,299/mo	Visit
RxSpan MD	brand	$1,299/mo	Visit
Effecty	brand	$1,300/mo	Visit
Ark Health	brand	$1,399/mo	Visit
Better U Care	brand	$1,399/mo	Visit
Elevated Health	brand	$1,399/mo	Visit
Eve	brand	$1,399/mo	Visit
Fridays	brand	$1,498/mo	Visit
NuuVim	brand	$1,498/mo	Visit
DudeMeds	brand	$1,585/mo	Visit
Superpower	brand	$1,799/mo	Visit
Concierge MD LA	brand	$1,999/mo	Visit

Short verdict pages setting Ozempic against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.

Ozempic vs Mounjaro

Two diabetes drugs prescribed off-label for weight. SURPASS-2 compared them directly at 40 weeks (11.2 kg against 5.7 kg), but only Ozempic has finished a cardiovascular outcomes trial.

Last verified 2026-05-27

Ozempic vs Rybelsus

The same molecule from the same maker, as a daily tablet and a weekly injection. Only about 1% of the tablet gets in, which explains almost every difference between them.

Last verified 2026-05-27

Ozempic vs Zepbound

Different molecules, different labels, and a head-to-head that favors one clearly: 20.2% against 13.7% at 72 weeks in SURMOUNT-5.

Last verified 2026-05-27

Ozempic vs Wegovy

The same molecule from the same maker under two names, with two labels, two dose ceilings and two entirely different coverage stories. This confusion costs people money every day.

Last verified 2026-05-27

Ozempic vs Foundayo

A weekly diabetes injection with proven cardiac benefit against a daily weight pill approved April 2026. Each holds exactly what the other lacks.

Last verified 2026-05-27

Ozempic vs Trulicity

Two weekly diabetes injections, tested directly against each other. Ozempic wins on blood sugar and weight; Trulicity holds the broader cardiac indication and the pediatric one.

Last verified 2026-05-28

See all drug-vs-drug verdicts.

The trials that produced the Ozempic label, taken endpoint by endpoint, with the figures read off the source.

SUSTAIN-6

SUSTAIN-6 was designed as a safety trial and returned a benefit. Across a median 2.1 years, in 3,297 people whose diabetes came with high cardiac risk, the three-part endpoint hit 6.6% of the semaglutide group and 8.9% of the placebo group. It established the cardiovascular signal that SELECT would later confirm in a population without diabetes, and it is the trial behind Ozempic's cardiovascular labeling.

Phase 3 · N=3,297 · Last verified 2026-05-28

FLOW

FLOW asked whether semaglutide slows kidney disease, in 3,533 people whose type 2 diabetes had damaged their kidneys, tracked for a median 3.4 years. The composite outcome — kidney failure, sustained eGFR decline, or renal or cardiovascular death — occurred in 18.7% against 23.2% on placebo, a 24% relative reduction. The independent monitoring committee stopped it early because the benefit was clear enough that continuing the placebo arm was no longer justified.

Phase 3b · N=3,533 · Last verified 2026-05-28

SUSTAIN-7

SUSTAIN-7 compared semaglutide against dulaglutide head-to-head at matched dose levels in 1,201 people living with type 2 diabetes across 40 weeks. Semaglutide 0.5 mg lowered HbA1c 1.5 points against dulaglutide 0.75 mg's 1.1, with the same direction at the higher pairing, and produced more weight loss at both. It is one of the few direct comparisons between two weekly GLP-1s and it settled which is the more potent.

Phase 3b · N=1,201 · Last verified 2026-05-28

Questions people actually asked about Ozempic in named subreddits, each answered from the published trial data.

Semaglutide Side Effects: 10 Questions, Answered From the Trials

10 questions · 15 PubMed citations

Last verified 2026-05-27

GLP-1 Coverage: the 10 Questions People Ask After a Denial

10 questions · 12 PubMed citations

Last verified 2026-05-28

Injecting a GLP-1: 10 Technique Questions, Answered

10 questions · 11 PubMed citations

Last verified 2026-05-28

One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.

Missed an Ozempic Dose? The Five-Day Window Explained

Ozempic's forgiveness window is five days from the day the shot was due, which is longer than the four-day window on tirzepatide — one reason applying a rule learned on another GLP-1 gets people into trouble. This page covers the decision, the 48-hour minimum between any two injections, and the far murkier question of what to do when the gap has run to weeks rather than days.

4 min read · Last verified 2026-05-27

GLP-1 Injection Sites: Rotation, Technique and the Lump to Avoid

Every weekly GLP-1 permits the same three injection sites and every one of them tells you to move around. The reason is a lump called lipohypertrophy — thickened fat that soaks up the drug at an unpredictable rate. When absorption becomes erratic so does appetite suppression, and a stalled month gets blamed on the dose when the cause is a favorite square inch of belly.

4 min read · Last verified 2026-05-28

Switching Between GLP-1s: Why You Start at the Bottom Again

Switching is common — a formulary changes, side effects bite, or you reach the top of a ladder with weight still to lose — and no label tells you how to do it. The rule that surprises people is that you go back to the bottom even though you have been on a GLP-1 for a year. Tolerating one of these drugs does not buy you tolerance of another, because they do not act on the same receptors.

5 min read · Last verified 2026-05-28

The peer-reviewed studies on Ozempic and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.

The 10 Semaglutide Weight-Loss Trials That Matter (2026)

Semaglutide has been tested more thoroughly for weight than any drug before it, and the ten trials below are the ones that changed something: the dose we use, the label it carries, what happens when you stop, and whether it does anything beyond the scale. Each entry gives the PMID, the design, and the figure that mattered.

10 ranked papers · Last verified 2026-08-16

The 10 Cardiovascular Outcome Trials Behind the GLP-1 Class (2026)

The cardiovascular evidence for this class is now broad enough to compare with statins: more than 80,000 patients across ten major trials. These are the ones that changed a label or a guideline — plus ELIXA, which found no benefit at all and remains the most useful negative result in the field.

10 ranked papers · Last verified 2026-08-16

The 10 Kidney Trials Behind the GLP-1 Class (2026)

For most of the last decade the kidney case for these drugs was assembled from secondary endpoints inside trials designed to measure something else. FLOW finally tested it directly in 2024 and produced the first kidney label in the class. These are that trial and the nine analyses that made anyone think it was worth running.

10 ranked papers · Last verified 2026-08-16

Every Published Retatrutide Trial (2026): the 24.2% Drug

Retatrutide is the drug people ask about most and can legitimately get least, because every result below is phase 2 or earlier. The headline is real — 24.2% at 48 weeks, beating tirzepatide's ceiling — and so is the caveat: the phase 3 program is still running and nothing from it has been published. These ten papers are the entire evidence base.

10 ranked papers · Last verified 2026-08-16

Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.

Muscle Loss: Drug Versus Dieting

Across 20 trials in 15,782 people, the share of weight lost as lean mass was the same on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.

6 min read1 citation

GLP-1s and Atrial Fibrillation: Reading a 42% Headline

A meta-analysis of ten trials in 12,651 patients found a 42% lower risk of new atrial fibrillation on semaglutide. None of those trials was designed to measure it, and the absolute numbers were never published.

6 min read3 citations

Burping, Reflux and Gas on a GLP-1: The Label's Widest Gap

Eructation runs under 1% on placebo against 7% on Wegovy: a sevenfold difference, and the widest relative gap in the adverse-reactions table. Reflux is a much smaller increase than people expect.

6 min read3 citations

Semaglutide and Knee Osteoarthritis: The Number Behind the Headline

A 68-week randomized trial cut WOMAC pain scores by 41.7 points on semaglutide and 27.5 on placebo. The drug's own contribution is the 14.2-point gap.

6 min read2 citations

Constipation on a GLP-1: What the Labels Report and What Actually Helps

The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. Here is why it outlasts the nausea, and where the confident advice online runs ahead of the evidence.

6 min read9 citations

GLP-1 Pancreatitis and Gallbladder Risk: What the Labels Counted

Two labeled warnings that are not the same kind of problem. Gallbladder disease tracks with rapid weight loss and is well counted; pancreatitis is rarer, was an exclusion criterion in the pivotal trials, and the database studies disagree.

12 min read19 citations

Frequently Asked Questions

FDA-approved for glycemic control in type 2 diabetes (December 2017); FDA-approved to reduce cardiovascular risk in adults with T2DM and established CVD (2020). Weight loss is off-label use.

What you pay for Ozempic turns on who is selling it and in what form. Uninsured, the branded product runs roughly $1,000 to $1,600 a month; compounded versions through telehealth sellers usually land between $129 and $400. The table above carries the current figures from our register. Before you commit, check whether a manufacturer savings program applies to you.

Ozempic is prescription-only, so someone licensed has to write it — your own doctor, an endocrinologist, or one of the telehealth sellers above. For compounded versions the telehealth route is usually both quicker and cheaper out of pocket than a traditional pharmacy.

Sources & methodology — as of September 2026

1.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
2.SUSTAIN-6 Trial — Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (Marso SP et al.)— New England Journal of Medicine.PMID: 27633186.
3.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Glossary

The words sellers use, defined. Tap any term.

Semaglutide · Drugs and brands
Wegovy · Drugs and brands
Rybelsus · Drugs and brands
GLP-1 receptor · Mechanism
Off-label use · Insurance and regulatory
FDA Drug Shortage List · Insurance and regulatory
Ozempic face · Side effects

Ozempic Guide

At a Glance

How Ozempic Works

Dosing Schedule

Side Effects

Clinical Trial Results

Where to Get Ozempic

Gala

MEDGm

RxSpan MD

Luvo Health

DudeMeds

Care Bare Rx

Cost Comparison

Ozempic Head-to-Head Comparisons

Pivotal Ozempic Trial Walkthroughs

Ozempic Patient Questions, Answered

Ozempic Reference Cards

Ranked PubMed Studies on Ozempic

Related Research on Ozempic

Frequently Asked Questions

Glossary